Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.68 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.68 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LDHA | P00338 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.37 |
| ▸ | TYR | P14679 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sucrose SCHEMBL301783 | 1.00 | CDK1 (0.68) | CDK1CCNB1CA2CA9MEN1 | |
| Sucrose SCHEMBL8718558 | 1.00 | CDK1 (0.68) | CDK1CCNB1CA2CA9MEN1 | |
| Sucrose SCHEMBL10910573 | 1.00 | CDK1 (0.68) | CDK1CCNB1CA2CA9MEN1 | |
| Sucrose SCHEMBL8323806 | 0.99 | CDK1 (0.67) | CDK1CCNB1CA2CA9MEN1 | |
| Sucrose SCHEMBL11039870 | 0.97 | CDK1 (0.68) | CDK1CCNB1CA2CA9MEN1 | |
| Sucrose SCHEMBL23886158 | 0.96 | CDK1 (0.64) | CDK1CCNB1CA2CA9MEN1 | |
| Sucrose SCHEMBL17801786 | 0.96 | CDK1 (0.64) | CDK1CCNB1CA2CA9MEN1 | |
| Sucrose SCHEMBL15111218 | 0.95 | CDK1 (0.71) | CDK1CCNB1CA2CA9MEN1 | |
| Sucrose SCHEMBL5490627 | 0.95 | CDK1 (0.71) | CDK1CCNB1CA2CA9MEN1 | |
| Sucrose SCHEMBL15111439 | 0.95 | CDK1 (0.71) | CDK1CCNB1CA2CA9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 268 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10413543-B2 | Stable multiparticulate pharmaceutical composition of rosuvastatin | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2019-09-17 | — | — | US | claimed |
| US-9974746-B2 | Reduction of flake-like aggregation in nanoparticulate active agent compositions | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-05-22 | — | — | US | claimed |
| EP-2004672-B1 | A PROCESS FOR CONCENTRATION OF A POLYPEPTIDE | SHIRE PHARMACEUTICALS IRELAND LTD (IE) | 2015-08-19 | — | — | EP | claimed |
| CN-104490837-A | Oral preparation of monosialotetrahexosyl ganglioside sodium | HARBIN MEDICAL UNIVERSITY TECHNOLOGY DEV HEADQUARTER | 2015-04-08 | — | — | CN | claimed |
| EP-1328664-B1 | A MULTISTEP PROCESS FOR RECOVERING BETAINE, ERYTHRITOL, INOSITOL, SUCROSE, MANNITOL, GLYCEROL AND AMINO ACIDS FROM A PROCESS SOLUTION USING A WEAKLY ACID CATION EXCHANGE RESIN | FINNFEEDS FINLAND OY (FI) | 2006-06-07 | — | — | EP | claimed |
| US-4166807-A | IRON, SULFUR, METAL HALIDE | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1979-09-04 | — | — | US | claimed |
| CN-118028157-A | Zymophyte agent for improving total flavone content in fermented Chinese herbal medicine and application thereof | 湖南农业大学 | 2024-05-14 | — | — | CN | disclosed |
| WO-2024089634-A1 | IMMUNOGENIC COMPOSITIONS AGAINST INFLUENZA AND RSV | PFIZER INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| CN-117250352-B | Pepsin detection kit | 聚诚(北京)生物科技有限责任公司 | 2024-02-13 | — | — | CN | disclosed |
| CN-117250352-A | Pepsin detection kit | 聚诚(北京)生物科技有限责任公司 | 2023-12-19 | — | — | CN | disclosed |
| US-11731961-B2 | Phenyl propionic acid derivatives and uses thereof | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-08-22 | — | — | US | disclosed |
| EP-4218808-A2 | ADJUVANT AND VACCINE COMPOSITIONS | Advanced BioAdjuvants, LLC (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230158140-A1 | ADJUVANT AND VACCINE COMPOSITIONS | ADVANCED BIOADJUVANTS LLC | 2023-05-25 | — | — | US | disclosed |
| EP-0201071-A2 | 2-Substituted-1-naphthols as 5-lipoxygenase inhibitors | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1986-11-12 | — | — | EP | disclosed |
| EP-0033518-A1 | Crystalline salts of a cephalosporin, their preparation and pharmaceutical compositions containing them | CIBA-GEIGY AG (CH) | 1981-08-12 | — | — | EP | disclosed |
| EP-0027991-A1 | Use of combination of compounds for alleviating pain | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-05-06 | — | — | EP | disclosed |
| US-4264573-A | TABLETS CONTAINING LITHIUM CARBONATE AS THE ACTIVE INGREDIENT HAS SLOW IN VIVO RELEASE | ROWELL LABORATORIES, INC. (US) | 1981-04-28 | — | — | US | disclosed |
| US-4260629-A | Treating pain with acetaminophen and 1,4-dimethyl-5-p-chlorobenzoyl-pyrrole-2-acetic acid | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-04-07 | — | — | US | disclosed |
| US-4207339-A | Anti-ulcer pharmaceutical composition containing inositol hexasulfate or an alkaline metal salt thereof as active ingredient | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1980-06-10 | — | — | US | disclosed |
| US-4041161-A | ANTIBIOTICS | CIBA-GEIGY CORPORATION (US) | 1977-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731961-B2 | Phenyl propionic acid derivatives and uses thereof | GPR119, GPR65, GPR55 | CDK1 4673/4885CCNB1 4293/4885CA2 706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.